Pharmacological management of heart failure with reduced EF

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorAlabbas, Mohammad
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2023-05-11T11:19:40Z
dc.date.available2023-05-11T11:19:40Z
dc.date.created2023-02-10
dc.description.abstractThis thesis aims to highlight the pharmacological agents used to treat chronic heart failure with reduced EF. Heart failure with reduced ejection fraction (HFrEF) occurrence might have risen over the previous 3 decades as a result of the emergence of numerous innovative pharmaceutical substances. Approximately 10% of sick people move forwards to much more developed phases of the disease, which are distinguished by elevated percentages of death rates, hospital admissions, as well as poor performance of living. Although being out on the best possible pharmacological, surgical, including device treatments, progressive HFrEF affected patients have persisting or developing indications of serious HF comparable to NYHA classes III or IV. Nevertheless, due to methodological limitations like decreased blood pressure as well as renal problems, a subgroup of sufferers having advanced HF, these kind of with the greatest severe forms, are been frequently underrepresented in the significant tests illustrating the effectiveness as well as reduced side effects of the medications used during HFrEF. As a result, individuals experiencing the greatest severe forms of HFrEF may not certainly benefit from the findings of many major research. Therefore, the effectiveness and tolerance of pharmacological therapy based on guidelines in individuals with the most developed forms of HFrEF frequently stay unknown, therefore this information is critical for the scheduling as well as management of recommendation considered for therapeutic strategies.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent36
dc.identifier.urihttps://hdl.handle.net/2437/353053
dc.language.isoen
dc.subjectHeart failure
dc.subjectcongestive heart failure
dc.subjectvasopressin receptor antagonists
dc.subject.dspaceDEENK Témalista::Orvostudomány
dc.titlePharmacological management of heart failure with reduced EF
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)